POSSIBILITIES OF APPLICATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE CLINIC OF INTERNAL DISEASES
Abstract
Approaches to glycemic control of people with type 2 diabetes mellitus shouldn’t now restrict striving to achieve and maintain the target glycosylated hemoglobin level. Currently, there are classes of antihyperglycemic drugs that, along with an effective decrease in glycemia, are capable of providing significant organoprotective effects. One of these new classes of antihyperglycemic drugs are inhibitors of sodium-glucose co-transporter 2. Until now, these drugs are little known to the domestic physician of general practice, since they are used very rarely and do not find their proper place in prescriptions. Meanwhile, their ability to favorably influence the cardiovascular and renal prognosis in people with type 2 diabetes, as well as in people without diabetes, allows us to count on the expansion of their use in endocrinological, cardiological and nephrological practice.
References
1. Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р., Токмакова А.Ю., Никонова Т.В., Суркова Е.В., Кононенко И.В., Егорова Д.Н., Ибрагимова Л.И., Шестакова Е.А., Клефортова И.И., Скляник И.А., Ярек-Мартынова И.Я., Северина А.С., Мартынов С.А., Викулова О.К., Калашников В.Ю., Бондаренко И.З., Гомова И.С., Старостина Е.Г., Аметов А.С., Анциферов М.Б., Бардымова Т.П., Бондарь И.А., Валеева Ф.В., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., Руяткина Л.А., Суплотова Л.А., Ушакова О.В., Халимов Ю.Ш. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23 (2S): 4-102. doi: 10.14341/DM12507
2. Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы: российский кардиологический журнал. 2020; 25 (4): 3858. doi: 10.15829/1560-4071-2020-3858
3. Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. и др. Лекции по внутренним болезням в период пандемии COVID-19: учебное пособие. Донецк; 2021. 486.
4. Ворожцова И.Н., Будникова О.В., Афанасьев С.А., Кондратьева Д.С. Влияние сахарного диабета 2-го типа на миокард пациентов с ишемической болезнью сердца. Сибирский журнал клинической и экспериментальной медицины. 2018; 33 (1): 14-20. doi: 10.29001/2073-8552-2018-33-1-14-20
5. Томилина НА. Хроническая болезнь почек. Избранные главы нефрологии. М.: ГЭОТАР-Медиа; 2017. 136.
6. Gomez L.A., Lei Y., Devarapu S.K., Anders H.J. The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’- implications for pre-clinical research and drug testing. Nephrol Dial Transplant. 2018; 33: 1292-1304. doi: 10.1093/ndt/gfx219
7. Смирнов А.В., Добронравов В.А., Кисина А.А. и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология. 2015; 19 (1): 67-77.
8. Pugliese G., Penno G., Natali A. et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on «The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function». J Nephrol. 2020; 33 (1): 9-35. doi: 10.1007/s40620-019-00650-x
9. Herrington W.G., Preiss D., Haynes R. et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clinical Kidney Journal. 2018; 11 (6): 749-761. doi: 10.1093/ckj/sfy090
10. Lamos E.M., Younk L.M., Davis S.N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Exp Opin Drug Metab Toxicol. 2013; 9 (6): 763-75.
11. American Diabetes Association; 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2020. Diabetes Care. 2020; 43 (Suppl. 1): S111-S134. doi: 10.2337/dc20-s010
12. Bonora B.M., Avogaro A., Fadini G.P. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; 13: 161-174. doi: 10.2147/DMSO.S233538
13. Heerspink H.J.L., Stefansson B.V., Chertow G.M. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35: 274-282. doi: 10.1093/ndt/gfz290
14. Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393: 31-39. doi: 10.1016/S0140-6736(18)32590-X
15. Täger T., Atar D., Agewall S. et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev. 2021; 26: 1421-1435. doi: 10.1007/s10741-020-09954-8
16. Packer M., Anker S.D., Butler J. et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; 2: 1025-1029. doi: 10.1001/jamacardio.2017.2275
17. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61: 2108-2117. doi: 10.1007/s00125-018- 4670-7.
18. Goldberg L.R. The Pleiotropic Effects of SGLT2 Inhibitors Remodeling the Treatment of Heart Failure. Journal of American College of Cardiology. 2021; 77 (3): 256-258. doi: 10.1016/j.jacc.2020.11.029
19. Hatanaka T., Ogawa D., Tachibana H. et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect. 2016; 4 (2): 00239. doi: 10.1371/journal.pone.0054442
20. Багрий А.Э., Хоменко М.В., Шверова О.И., Титиевская А.И. Подходы к лечению диабетической нефропатии (обзор литературы). Нефрология. 2021; 25 (1): 18-30. doi: 10.36485/1561-6274-2021-25-1-18-30
21. Некрасов А.А., Тимощенко Е.С., Стронгин Л.Г., Некрасова Т.А., Баранова А.А., Ботова С.Н., Тимощенко М.В., Ярославцева М.А. Влияние эмпаглифлозина на развитие хронической сердечной недостаточности после инфаркта миокарда у пациентов с сахарным диабетом 2 типа по данным 12-месячного проспективного исследования. Сахарный диабет. 2019; 22 (4): 348-357. doi: 10.14341/DM10099
22. Lopaschuk G.D., Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review. JACC: Basic to Translational Science. 2020; 5 (6): 632-644. doi: 10.1016/j.jacbts.2020.02.004
23. Ferreira J.P., Pocock S.J., Anker S.D., Butler J. et al. Interplay of Mineralocorticoid Receptor Antagonists and empagliflozin in Heart Failure EMPEROR-Reduced: Journal of American College of Cardiology;2021; 77 (11): 1397-1407. doi: 10.1016/J.JACC.2021.01.044
24. Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2-го типа у пациентов с сахарным диабетом 2-го типа в сочетании с гиперурикемией и подагрой. Тер. Архив. 2020; 95 (5): 110-118. doi: 10.26442/00403660.2020.05.000633
25. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes: N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
26. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377 (7): 644-657. doi: 10.1056/NEJMoa1611925
27. McMurray J.J.V., DeMets D.L., Inzucchi S.E. et al. A trial to evaluate the effect of the sodiumglucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21 (5): 665-675. doi: 10.1002/ejhf.1432
28. Zelniker T.A., Wiviott S.D., Raz I., Im K. et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139 (17): 2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
29. Inzucchi S.E., Docherty K.F., Køber L. et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021; 44 (2): 586-594. doi: 10.2337/DC20-1675
2. Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы: российский кардиологический журнал. 2020; 25 (4): 3858. doi: 10.15829/1560-4071-2020-3858
3. Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. и др. Лекции по внутренним болезням в период пандемии COVID-19: учебное пособие. Донецк; 2021. 486.
4. Ворожцова И.Н., Будникова О.В., Афанасьев С.А., Кондратьева Д.С. Влияние сахарного диабета 2-го типа на миокард пациентов с ишемической болезнью сердца. Сибирский журнал клинической и экспериментальной медицины. 2018; 33 (1): 14-20. doi: 10.29001/2073-8552-2018-33-1-14-20
5. Томилина НА. Хроническая болезнь почек. Избранные главы нефрологии. М.: ГЭОТАР-Медиа; 2017. 136.
6. Gomez L.A., Lei Y., Devarapu S.K., Anders H.J. The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’- implications for pre-clinical research and drug testing. Nephrol Dial Transplant. 2018; 33: 1292-1304. doi: 10.1093/ndt/gfx219
7. Смирнов А.В., Добронравов В.А., Кисина А.А. и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология. 2015; 19 (1): 67-77.
8. Pugliese G., Penno G., Natali A. et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on «The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function». J Nephrol. 2020; 33 (1): 9-35. doi: 10.1007/s40620-019-00650-x
9. Herrington W.G., Preiss D., Haynes R. et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clinical Kidney Journal. 2018; 11 (6): 749-761. doi: 10.1093/ckj/sfy090
10. Lamos E.M., Younk L.M., Davis S.N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Exp Opin Drug Metab Toxicol. 2013; 9 (6): 763-75.
11. American Diabetes Association; 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2020. Diabetes Care. 2020; 43 (Suppl. 1): S111-S134. doi: 10.2337/dc20-s010
12. Bonora B.M., Avogaro A., Fadini G.P. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; 13: 161-174. doi: 10.2147/DMSO.S233538
13. Heerspink H.J.L., Stefansson B.V., Chertow G.M. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35: 274-282. doi: 10.1093/ndt/gfz290
14. Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393: 31-39. doi: 10.1016/S0140-6736(18)32590-X
15. Täger T., Atar D., Agewall S. et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev. 2021; 26: 1421-1435. doi: 10.1007/s10741-020-09954-8
16. Packer M., Anker S.D., Butler J. et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; 2: 1025-1029. doi: 10.1001/jamacardio.2017.2275
17. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61: 2108-2117. doi: 10.1007/s00125-018- 4670-7.
18. Goldberg L.R. The Pleiotropic Effects of SGLT2 Inhibitors Remodeling the Treatment of Heart Failure. Journal of American College of Cardiology. 2021; 77 (3): 256-258. doi: 10.1016/j.jacc.2020.11.029
19. Hatanaka T., Ogawa D., Tachibana H. et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect. 2016; 4 (2): 00239. doi: 10.1371/journal.pone.0054442
20. Багрий А.Э., Хоменко М.В., Шверова О.И., Титиевская А.И. Подходы к лечению диабетической нефропатии (обзор литературы). Нефрология. 2021; 25 (1): 18-30. doi: 10.36485/1561-6274-2021-25-1-18-30
21. Некрасов А.А., Тимощенко Е.С., Стронгин Л.Г., Некрасова Т.А., Баранова А.А., Ботова С.Н., Тимощенко М.В., Ярославцева М.А. Влияние эмпаглифлозина на развитие хронической сердечной недостаточности после инфаркта миокарда у пациентов с сахарным диабетом 2 типа по данным 12-месячного проспективного исследования. Сахарный диабет. 2019; 22 (4): 348-357. doi: 10.14341/DM10099
22. Lopaschuk G.D., Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review. JACC: Basic to Translational Science. 2020; 5 (6): 632-644. doi: 10.1016/j.jacbts.2020.02.004
23. Ferreira J.P., Pocock S.J., Anker S.D., Butler J. et al. Interplay of Mineralocorticoid Receptor Antagonists and empagliflozin in Heart Failure EMPEROR-Reduced: Journal of American College of Cardiology;2021; 77 (11): 1397-1407. doi: 10.1016/J.JACC.2021.01.044
24. Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2-го типа у пациентов с сахарным диабетом 2-го типа в сочетании с гиперурикемией и подагрой. Тер. Архив. 2020; 95 (5): 110-118. doi: 10.26442/00403660.2020.05.000633
25. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes: N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
26. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377 (7): 644-657. doi: 10.1056/NEJMoa1611925
27. McMurray J.J.V., DeMets D.L., Inzucchi S.E. et al. A trial to evaluate the effect of the sodiumglucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21 (5): 665-675. doi: 10.1002/ejhf.1432
28. Zelniker T.A., Wiviott S.D., Raz I., Im K. et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139 (17): 2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
29. Inzucchi S.E., Docherty K.F., Køber L. et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021; 44 (2): 586-594. doi: 10.2337/DC20-1675
Published
2023-02-24
How to Cite
БАГРИЙ, А. Э. et al.
POSSIBILITIES OF APPLICATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE CLINIC OF INTERNAL DISEASES.
University Clinic, [S.l.], n. 4(45), p. 58-64, feb. 2023.
ISSN 1819-0464. Available at: <http://journal.dnmu.ru/index.php/UC/article/view/751>. Date accessed: 18 may 2024.
Section
Reviews
